HKSE - Delayed Quote HKD

Brii Biosciences Limited (2137.HK)

1.160 +0.070 (+6.42%)
At close: April 26 at 4:08 PM GMT+8

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Dr. Zhi Hong Ph.D. Co-founder, Executive Chairman of the Board & CEO 10.18M -- 1964
Dr. Ankang Li C.F.A., J.D., Ph.D. Chief Financial & Strategy Officer, Company Secretary and Executive Director 6.48M -- 1978
Dr. Eleanor de Groot Ph.D. Chief Technology Officer -- -- 1969
Dr. Brian Alvin Johns Ph.D. Chief Scientific Officer -- -- --
Sarah Qiu Associate Director of Investor Relations -- -- --
Ms. Karen Del Barrio Neuendorff Chief People Officer & Head of Human Resources -- -- 1976
Mr. Coy Stout Head of Patient Advocacy -- -- 1972
Dr. Lianhong Xu Ph.D. Head of Discovery -- -- 1967
Dr. Qing Zhu Ph.D. Head of China Research & Development -- -- 1968
Dr. David Margolis M.D., M.P.H. Chief Medical Officer -- -- 1975

Brii Biosciences Limited

Building 7, International Science Park
3rd Floor, Zhongguancun Dongsheng No. 1 North Yongtaizhuang Road Haidian District
Beijing, 100192
China
https://www.briibio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
128

Description

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trail and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. The company was incorporated in 2017 and is headquartered in Beijing, China.

Corporate Governance

Brii Biosciences Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Mar 25, 2024
Brii Biosciences Limited Earnings Call

Related Tickers